Mentorship

Marcus Bosenberg MD, PhD, is a physician scientist who directs a leading melanoma research laboratory, is Co-Leader of the Cancer Immunology Program of Yale Cancer Center, Director of the Yale Center for Immuno-Oncology, Contact PI of the Yale SPORE in Skin Cancer,  Director of the Center for Precision Cancer Modeling, and is a practicing dermatopathologist at Yale Dermatopathology through Yale Medicine.In his research, Dr. Bosenberg studies factors that regulate anti-cancer immune responses. His laboratory has developed several widely utilized mouse models in order to study how melanoma forms and progresses, to test new cancer therapies, and how the immune system can be stimulated to fight cancer. He works to translate basic scientific findings into improvements in cancer diagnosis and therapy. He has published over 200 peer-reviewed articles and is a member of the Yale Cancer Center Executive Committee.Dr. Bosenberg mentors undergraduate, graduate, medical, and MD-PhD students in his laboratory, teaches at Yale School of Medicine, and trains resident physicians, fellows, and postdoctoral fellows.

Barbara Burtness, MD is Professor of Medicine (Medical Oncology) at the Yale School of Medicine, Chief Translational Research Officer, and Associate Cancer Center Director for Translational Research at the Yale Cancer Center. She serves as Co-Leader of the Developmental Therapeutics Program, Division Chief for Head and Neck/Sarcoma Oncology, and Director of the Yale Head and Neck Specialized Program of Research Excellence. Dr. Burtness is internationally recognized for her research in head and neck cancer. She chairs the ECOG-ACRIN Cooperative Group Head and Neck Cancer Therapeutics Committee and the ECOG-ACRIN Task Force for the Advancement of Women, and leads national and international trials of targeted therapy in head and neck cancer. Her laboratory studies synthetic lethal therapeutic strategies in head and neck cancer and the targeting of aurora kinase A to overcome adaptive resistance to EGFR inhibition and - in lung cancer- to direct KRAS inhibition.

Lieping Chen, MD, PhD, is an immunologist and physician-scientist. His research focuses on basic T cell biology and the translation of laboratory discoveries into clinical therapies, with a primary emphasis on cancer immunotherapy. Dr. Chen’s laboratory is renowned for the 1999 discovery of the B7-H1 (PD-L1) molecule and the subsequent identification of the PD-1/PD-L1 pathway as a critical mechanism of immune evasion in the tumor microenvironment. This breakthrough, hailed as the #1 Breakthrough of the Year by Science magazine in 2013, led to the development of anti-PD-1/PD-L1 antibodies, which are now global standards of care for a broad spectrum of advanced cancers. A prolific investigator with over 400 peer-reviewed publications, Dr. Chen held faculty positions at the Mayo Clinic, Johns Hopkins University, and scientist positions in the Bristol-Myers Squibb Co. before joining Yale University. He is a member of the National Academy of Sciences, the National Academy of Medicine, and a Fellow of the American Association for Cancer Research (AACR).

The DiMaio laboratory is studying the molecular mechanisms of how human papillomaviruses enter cells, with a particular focus on identifying the cellular proteins that mediate virus entry and intracellular trafficking and determining their molecular mechanisms of action. In addition, it is using viral transmembrane proteins as a basis to develop a class of artificial small transmembrane proteins with a variety of biological activities, including the ability to form tumors and confer resistance to virus infection. Some of these proteins are the simplest proteins ever described and their study will reveal new features of protein action and the basis for specificity in protein-protein interactions.

Dr. Flavell is Sterling Professor of Immunobiology at Yale University School of Medicine, and an Investigator of the Howard Hughes Medical Institute. He received his B.Sc. (Honors) in 1967 and Ph.D. in 1970 in biochemistry from the University of Hull, England, and performed postdoctoral work in Amsterdam (1970-72) with Piet Borst and in Zurich (1972-73) with Charles Weissmann. Before accepting his current position in 1988, Dr. Flavell was first Assistant Professor (equivalent) at the University of Amsterdam (1974-79); then Head of the Laboratory of Gene Structure and Expression at the National Institute for Medical Research, Mill Hill, London (1979-82); and subsequently President and Chief Scientific Officer of Biogen Research Corporation, Cambridge, Massachusetts (1982-88). Dr. Flavell is a fellow of the Royal Society, a member of the National Academy of Sciences as well as the National Academy of Medicine. Richard Flavell uses transgenic and gene-targeted mice to study Innate and Adaptive immunity, T cell tolerance and activation in immunity and autoimmunity,apoptosis, and regulation of T cell differentiation.

Radiation oncologist Peter M. Glazer, MD, PhD, is the chair of the Department of Therapeutic Radiology. He has dedicated his career to helping cancer patients receive the highest quality of care available in a supportive environment.“When patients are undergoing radiotherapy for cancer, it can be a sensitive and challenging time for them and their families,” he says. “Our team does everything possible to keep our patients safe and comfortable throughout treatment.” Dr. Glazer makes it his priority to provide patients seeking care at Smilow Cancer Hospital and its Care Centers with the most advanced technologies and evidence-based treatments. “We take great pride in giving our physicians the best tools to treat cancer,” he says.As a professor of both therapeutic radiology and genetics at Yale School of Medicine, Dr. Glazer researches new therapeutic strategies for treating cancer and the role of altered DNA repair in tumor progression. His research was recently recognized by the National Cancer Institute of the NIH with a prestigious Outstanding Investigator Award of $7 million that will support his efforts to develop novel DNA repair inhibitors for cancer therapy.

David A. Hafler, M.D. is the William S. and Lois Stiles Edgerly Professor and former Chairman Department of Neurology and Professor of Immunobiology, Yale School of Medicine, and was the Neurologist-in-Chief of the Yale-New Haven Hospital. Hafler graduated magna cum laude in 1974 from Emory University with combined B.S. and M.Sc. degrees in biochemistry, and the University of Miami School of Medicine in 1978. He completed his internship in internal medicine at Johns Hopkins followed by a neurology residency at Cornell Medical Center-New York Hospital in New York. Hafler was trained in immunology with Henry Kunkel at the Rockefeller University and then at Harvard Medical School joining the Harvard faculty in 1984. He became the Breakstone Professorship of Neurology at Harvard 1999 and was a founding Associated Member of the Broad Institute at MIT. His discoveries in the pathogenesis and treatment of multiple sclerosis have led to fundamental understanding of the disease and the development of novel treatments. His seminal work includes identification of circulating human autoreactive T cells and the mechanisms that underlie their dysregulation with the discovery of human regulatory T cells. He co-led the discovery of genetic variants causing MS and demonstrated how these variants alter immune responses in relationship to environmental factors such as salt allowing activation of autoreactive T cells. Hafler was founder of the Federation of Clinical Immunology Societies and the International MS Genetic Consortium. He was a Jacob Javits Merit Award Recipient from the NIH and was awarded the Dystel Prize for MS research from the AAN, the University of Miami Annual Distinguished Alumni Award, the Raymond Adams Prize from the ANA and is the 2023 recipient of the 2023 AAI Steinman Award for Human Immunology Research. Hafler is an Honorary Member of the Scandinavian Society for Immunology a Fellow in the American Association of Immunologist and the American Association for the Advancement of Science, and has been elected to the AOA Society, the American Society of Clinical Investigation, The Association of American Physicians, and the National Academy of Medicine.

Dr. Halene is a physician-scientist who received her MD degree at Eberhardt-Karls-University in Tübingen, Germany. She subsequently completed a postdoctoral fellowship in the laboratory of Donald B. Kohn at CHLA in Los Angeles and her residency in internal medicine in the traditional program at Yale New Haven Hospital. She completed her fellowship in hematology/oncology at Yale and joined the ladder faculty at YSM as an assistant professor in 2010. At that time she was also named director of the Hematology Tissue Bank for Yale Cancer Center. She was promoted to associate professor in 2016 and subsequently served as interim chief of the Section of Hematology prior to her appointment as chief of that section in 2020. Her laboratory studies hematopoiesis and myelopoiesis and in particular how mutations in splicing factors and perturbations in RNA modifications contribute to hematologic malignancies such as myelodysplasia and leukemia. Dr. Halene, in collaboration with the Flavell laboratory in the YSM Department of Immunobiology, has developed the first efficient xenotransplantation model in humanized mice to study myelodysplasia and enable testing of novel drug treatments. Dr. Halene’s research has garnered significant attention from the international community, as evidenced by numerous invited speaking engagements, an invitation to serve as a section editor on myeloid malignancies for a major journal, and publications in top tier journals in her field. In 2015 she was presented with the Sir William Osler Young Investigator Award and in 2019 was elected a member of the Interurban Clinical Club. Dr. Halene is director of the DeLuca Center for Innovation in Hematology Research. Through generous funding from The Frederick A. DeLuca Foundation, the center has established a comprehensive biospecimen bank, awarded pilot and career development grant funding to advance cutting-edge discoveries in hematologic malignancies and classical hematologic disorders. Meet Dr. Stephanie Halene>>

Dr. Roy Herbst is internationally recognized as one of the foremost leaders in the development of targeted and immune-based therapies for the treatment of lung cancer. His pioneering clinical studies investigating epidermal growth factor receptor (EGFR)-targeted agents in lung and head and neck cancers brought forth a new era in precision medicine and oncology. His translational research spurred the evolution of adaptive clinical trial design toward increasingly more personalized therapeutic approaches, and he was among the first to champion the use of targeted therapies during the earliest stages of disease. His groundbreaking studies have identified critical biomarkers of sensitivity and resistance to immunotherapy, helping to inform treatment decision-making. His work throughout the past three decades has significantly advanced the standard of care for patients with lung cancer, greatly enhancing survival and quality of life beyond what was previously thought to be possible. After earning B.S. and M.S. degrees from Yale University, Dr. Herbst earned his M.D. at Cornell University Medical College and his Ph.D. in Molecular Cell Biology at The Rockefeller University in New York City, New York. His postgraduate training included an internship and residency in Medicine at Brigham and Women’s Hospital in Boston, Massachusetts. His clinical fellowships in Medicine Oncology and Hematology were completed at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, respectively. Subsequently, Dr. Herbst completed an M.S. degree in Clinical Translational Research at Harvard University in Cambridge, Massachusetts. Prior to his appointment at Yale, Dr. Herbst was the Barnhart Distinguished Professor and Chief of the Section of Thoracic Medical Oncology in the Department of Thoracic/Head and Neck Medical Oncology, at The University of Texas M.D. Anderson Cancer Center in Houston, Texas. He also served as Professor in the Department of Cancer Biology and Co-Director of the Phase I Clinical Trials Program. Dr. Herbst traversed to the forefront of personalized medicine and immunotherapy early in his career, identifying key biomarkers and bringing novel targeted and immune-based treatments to patients by serving as principal investigator (PI) for seminal clinical trials testing these agents in advanced-stage lung cancers. This work led to the approval of several important targeted therapies (such as gefitinib, erlotinib, cetuximab, bevacizumab, and axitinib), that revolutionized the field and quickly became the standard of care. This research laid the groundwork for more recent paradigm-shifting studies led by Dr. Herbst investigating targeted agents in earlier stages of disease. One such study, the ADAURA trial, demonstrated the dramatic effect of the third generation EGFR-inhibitor osimertinib as an adjuvant therapy in early-stage resected non-small cell lung cancer, the results of which were published twice in the New England Journal of Medicine, and led to worldwide drug approval and expanded access for patients. He and his colleagues at Yale were also among the first to describe the PD-1/PD-L1 adaptive immune response in early phase trials and to offer clinical trials of the PD-L1 inhibitors atezolizumab and pembrolizumab to lung cancer patients. Dr. Herbst’s leadership in this arena has been formally recognized by his selection to deliver plenary presentations at the American Society of Clinical Oncology (ASCO) annual meetings in 2020 and 2023. Dr. Herbst’s work on umbrella trials, master protocols, and pragmatic trials has further galvanized the field of targeted therapy and cancer drug approvals by the United States (US) Food and Drug Administration (FDA). Nationally, he works closely with public-private partnerships to develop large master protocol clinical studies. He was co-leader of the Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination-1 (BATTLE-1) and subsequent BATTLE-2 clinical trial programs and was the founding PI of the Lung Master Protocol (Lung-MAP), a position he held for ten years. The Lung-MAP protocol utilizes patient biomarkers to choose treatments that are most likely to provide benefit. He testified on this before the US House of Representatives 21st Century Cures Committee and has helped solidify master protocols as the preferred clinical trial design by the FDA. He is currently the Chair Emeritus and Senior Advisor for the Lung-MAP trial through SWOG. Extending on the success of the Lung-MAP initiative, Dr. Herbst was instrumental in the design and implementation of the Pragmatica-Lung Cancer trial, modernizing and simplifying inclusion criteria to expand access to life-saving treatments to those patients who need it most, often from underserved and rural areas. As a testament to the efficiency of such a trial design, it has accrued 800 patients nationwide in just one year. Dr. Herbst is a highly respected clinician­ scientist who has been a champion of translational medicine for decades, recently authoring a high-profile review of the 20-year progress in lung cancer for the journal Nature that is widely cited. He has authored or co-authored more than 500 publications, including peer-reviewed journal articles, abstracts, and book chapters. His work has appeared in many prominent journals, such as the Journal of Clinical Oncology, Clinical Cancer Research, Lancet, and the New England Journal of Medicine. Work published in Nature was awarded the 2015 Herbert Pardes Clinical Research Excellence Award by the Clinical Research Forum. His abstracts have been presented at the annual meetings of ASCO, the American Association for Cancer Research (AACR), the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC), and the European Organization for Research and Treatment of Cancer, to name a few. In 2015, and again in 2020 and 2025, Dr. Herbst’s team at Yale was awarded a Lung Cancer SPORE (P50 grant) by the National Cancer Institute (NCI), which has identified new immunotherapies and mechanisms of sensitivity and resistance to EGFR targeted therapies. In 2017, he successfully helped establish and led the Yale-AstraZeneca Alliance, a strategic partnership that leverages the strengths of academia and industry working together to generate breakthroughs in cancer treatment and care. His work has also been funded by ASCO, AACR, the US Department of Defense, and by an AACR/Stand Up to Cancer Dream Team grant. Dr. Herbst is a Fellow of ASCO and a member of AACR, where he serves as Chair of the AACR Science Policy and Government Affairs Committee. He has been a major proponent of efforts to promote tobacco control and regulation (including e-cigarettes), authoring multiple policy statements and leading frequent Capitol Hill briefings. He has served on both the IASLC and AACR Board of Directors. He is a Fellow of the American College of Physicians and an elected member of the Association of American Physicians. He has served over ten years in non-consecutive terms as a member of the National Academy of Medicine’s (NAM’s) Cancer Policy Forum, now on his second term, for which he organized and chaired or co-chaired several meetings focused on policy issues in personalized medicine and tobacco control such as, “Policy Issues in the Development of Personalized Medicine in Oncology,” “Reducing Tobacco Related Cancer Incidence and Mortality,” “Optimizing Public-Private Partnerships (PPP) for Clinical Research,” and “Addressing the Impact of Tobacco and Alcohol Use on Cancer-Related Health Outcomes.” Most recently he led the authorship of the manuscript from the 2023 PPP meeting published in the Journal of the National Cancer Institute and is leading the writing team for the most recent workshop. For his lifetime achievement in scientific contributions to thoracic cancer research, Dr. Herbst was awarded the 2016 Paul A. Bunn, Jr. Scientific Award by the IASLC at their 17th WCLC in Vienna, Austria. He and his team at the Yale Cancer Center were awarded the 2018 Team Science Award from the Association for Clinical and Translational Science for their pioneering work in advancing our understanding of immunotherapy. In 2020, Dr. Herbst was awarded the AACR Distinguished Public Service Award for Exceptional Leadership in Cancer Science Policy. Dr. Herbst is the recipient of the 2022 Giants of Cancer Care® award for Lung Cancer and was honored by Friends of Cancer Research in 2021 as one of their 25 scientific and advocacy leaders who, through their work and partnership, have been instrumental over the course of the last 25 years in making significant advancements for patients. In 2024, Dr. Herbst became a member of the Board of Directors for Friends of Cancer Research. That year, he was also awarded the Ezra Greenspan Award from the Chemotherapy+ Foundation. In 2025, he was elected into the Connecticut Academy of Science and Engineering. Beyond Dr. Herbst’s exceptional research accomplishments, he remains a noted educator and teacher. Dr. Herbst is proud to serve as the creator and inaugural director of the Masters in Health Science in Clinical Investigation at the Yale Medical School, which provides training in, and integration of, translational research of all types. He has written chapters for major oncology textbooks (Devita, Frei) and is the Hematology/Oncology Section Editor for the upcoming 28th Edition of Goldman-Cecil Medicine. Since 2021, he has been the Co-Chair/Co-Director of the Robert A. Winn Excellence in Clinical Trials Award Program: Design and Implementation of Clinical Trials Workshop in collaboration with the AACR. Today, and throughout Dr. Herbst’s storied career, he has remained steadfastly committed to delivering exceptional and compassionate patient care, producing top-notch translational research, and providing enlightening educational experiences to trainees that will prepare them for successful and meaningful careers as healthcare providers and clinical researchers. He has and continues to promote an atmosphere of collegiality and collaboration, building translational bridges between basic and clinical researchers, as well as between academic and industry partners. Dr. Herbst inspires his peers, colleagues, and trainees to strive for excellence in the laboratory, clinic, classroom, and community, and his legacy will make an impact on patients for years to come.

Akiko Iwasaki, Ph.D. is a Sterling Professor of Immunobiology at the Yale University School of Medicine. Her research focuses on the mechanisms of immune defense against viruses at mucosal surfaces, which are a major site of entry for infectious agents. Professor Iwasaki received her Ph.D. in Immunology from the University of Toronto and completed her postdoctoral training with the National Institutes of Health before joining Yale’s faculty in 2000. She has been a Howard Hughes Medical Institute Investigator since 2014. Professor Iwasaki has received many awards and honors including the Keio Medical Science Prize in 2025, Forbes 50 over 50 Innovation 2024, TIME 100 Most Influential People 2024, TIME 100 HEALTH Most Influential People Affecting Global Health 2024, and the Else Kröner Fresenius Prize for Medical Research 2023. She was elected to the National Academy of Sciences in 2018, to the National Academy of Medicine in 2019, to the American Academy of Arts and Sciences in 2021 and was appointed President of American Associations of Immunologists (AAI) in 2023. Professor Iwasaki has been a leading scientific voice during the COVID-19 pandemic and is also well known for her Twitter advocacy on women and underrepresented minorities in the science and medicine fields. She was named to the 2023 STATUS list of the ultimate list of leaders in life sciences. Professor Iwasaki is the director of the Center for Infection and Immunity and is at the forefront of several long COVID investigations including the Mount-Sinai Yale Long COVID study, Yale LISTEN study, and Yale Paxlovid trial.

Dr. Kluger is a medical oncologist who sees patients with melanoma and renal cell carcinoma. Her research interests focus on developing new drug regimens and biomarkers predictive of response to therapies in melanoma and renal cell carcinoma. She participates in a number of clinical trials studying new agents for the treatment of these diseases, both targeting the immune system and the cancer cell. She runs an active research laboratory that studies tumor and immune cells from patients treated with novel therapies to determine mechanisms of resistance to therapy and mediators of toxicity from immune checkpoint inhibitors. The laboratory also conducts pre-clinical studies to improve treatment regimens for patients with melanoma, renal cell carcinoma or brain metastasis. Please visit the lab website at: https://sites.google.com/yale.... Learn more about Dr. Kluger>>

I have been working in the broad fields of bioinformatics, machine learning, applied mathematics and dynamics of quantum fields.  My current research interests relate to development of spectral methods and unsupervised & supervised deep learning approaches for analyzing high dimensional genomics, transcriptomics, epigenomics and proteomics data from various modalities.  I apply these methods in the context of cancer, immunobiology,  brain and phylogeny studies with the aim of revealing cell specific regulatory networks and characterizing biomarkers.

Diane Krause MD, PhD is Professor of Laboratory Medicine, Pathology and Cell Biology at Yale University; Associate Director of the Yale Stem Cell Center; and Director of the Clinical Cell Processing Laboratory. She received an Sc.B. degree in Biology from Brown University, and an MD and PhD degree from the University of Pennsylvania. After completing a residency in Clinical Pathology at the University of Pennsylvania, she performed post-doctoral studies at Johns Hopkins University. She runs a well-funded research laboratory focused on leukemogenesis, hematopoietic stem and progenitor cell fate specification clinical cell therapy and pluripotent stem cell differentiation down the parathyroid lineage. Watch a video with Dr. Diane Krause >>

Pat LoRusso brings more than 25 years of expertise in medical oncology, drug development, and early phase clinical trials. Prior to her Yale appointment, she served in numerous leadership roles at Wayne State University’s Barbara Karmanos Cancer Institute, most recently as director of the Phase I Clinical Trials Program and of the Eisenberg Center for Experimental Therapeutics.

Dr. Ma is Professor of Epidemiology at the Yale School of Public Health, and Co-Leader of the Cancer Prevention and Control Research Program at the Yale Comprehensive Cancer Center, Yale School of Medicine. She studies the etiology and health outcomes of different types of cancer, with a focus on pediatric cancer and malignancies of the hematopoietic system (e.g., leukemia, lymphoma, myelodysplastic syndromes, and myeloproliferative neoplasms). Her research has addressed the impact of immunological factors, chemical exposures, and genetic characteristics on the risk of cancer. In addition, she has assessed the patterns of care and cost implications of cancer screening and treatment in older adults.

Training Period: 1998-2003  Degree/Year: BS/MS-1995; PhD-2002; MD-2003  Source of Funding: MSTP Grant  1st Position: Resident, Therapeutic Radiology,Brigham and Women's Hospital, Boston, MA, research with J. Szostak.  Current Position: Asst Prof, Therapeutic Radiology, Yale U, New Haven, CT.

Katerina Politi studied Biology at the University of Pavia in Italy. She then moved to New York, where she obtained her PhD in Genetics and Development working with Argiris Efstratiadis at Columbia University. Following graduate school, she joined Harold Varmus's lab at Memorial Sloan-Kettering Cancer Center and began her work on the molecular basis of lung cancer. She continues this work at Yale as a Professor in the Department of Pathology and Yale Cancer Center.

David Rimm is the Anthony N. Brady Professor of Pathology in the Departments of Pathology and Medicine (Oncology) at the Yale University School of Medicine. He is the Director of Yale Pathology Tissue Services and the Lab for Quantitative Diagnostics in Anatomic Pathology. He completed an MD-PhD at Johns Hopkins University Medical School followed by a Pathology Residency at Yale and a Cytopathology Fellowship at the Medical College of Virginia. His research lab group focuses on quantitative pathology using the AQUA® technology invented in his lab, and other quantitative methods, with projects related to predicting response and resistance to both targeted and immune- therapy in cancer. His lab is involved in the use of new high-plex methods including digital spatial profiling (NanoString) for new biomarker discovery. He is also interested in translation of assays to the clinic and standardization of those assays for CLIA labs. The work is supported by grants from the NIH, BCRF, and sponsored research agreements from biopharma. He also serves on the CAP Immunohistochemistry committee and multiple scientific advisory boards for biotech and pharma. He is an author of over 500 peer-reviewed papers with an H-index of 120 and 8 patents.

Dr. Alessandro D. Santin, a native of Italy, graduated with honors from the University of Brescia, Italy and received his postgraduate training in Obstetrics & Gynecology at the same University. He served a fellowship in Gynecologic Oncology at the University of California, Irvine and an International Fellowship in the Division of Gynecologic Oncology at the University of Arkansas for Medical Sciences, Little Rock, Arkansas. In 2000 he became a Clinical Assistant Professor and in 2004 an Associate Professor with Tenure in the same Division. Watch a video with Dr. Alessandro Santin >> Dr. Santin joined the faculty in the Section of Gynecologic Oncology in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale as Professor as of July 2008. He was the recipient of the American Association young investigator award and the Italian Society of Gynecologic Oncologists award for translational science. Dr. Santin has more than 300 original research and peer-reviewed publications including multiple review articles and book chapters and he has written extensively on various topics, including cancer of the ovary, endometrium and cervix as well as on tumor immunology and immunotherapy. Dr. Santin's clinical interests include cancer of the ovary, uterus, vagina, cervix and vulva; intraperitoneal chemotherapy, tumor genetics, immunology and immunotherapy; tumor angiogenesis, radiation biology and experimental therapeutics in Gynecologic Oncology. His current research interests include immunotherapy for ovarian, cervical and endometrial carcinomas refractory to standard treatment modalities; development of therapeutic vaccines against Human Papillomavirus (HPV) infected genital tumors, and the use of monoclonal antibodies against chemotherapy resistant gynecologic malignancies. Dr. Santin is a member of the Society of Gynecologic Oncologists, the Gynecologic Oncology Group, The International Gynecologic Oncology Society, the American Medical Association, the American Society of Immunologists, the Italian Society of Gynecologic Oncologists, the American Association for Cancer Research and the American Society of Clinical Oncology.